MENLO PARK, Calif., Sept. 3, 2025 /PRNewswire/ -- MyOme, a leading clinical whole genome testing and polygenic risk modelling (PRS) company, today announced the launch of its Type 2 Diabetes (T2D) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results